A scientific rationale for choosing patients rather than normal subiects for Phase I studies

The determination of safety and adverse effects in Phase I together with investigations on the disposition and bioavailability of the drug often provide a better scientific and ethical basis if conducted with knowledge of the dose required to produce the desired pharmacologic effect. Because certain pharmacologic effects are specific for the disease state, Phase I studies on stich drugs should be conducted only in carefully selected patients with the appropriate disease.